Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
single-domain antibody BCMA CAR-T cells
- Development stage
- Preclinical
- Lead developer
- BC Cancer Research Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Single-domain antibody (sdAb) BCMA CAR-T cells are chimeric antigen receptor T-cell therapies engineered to target B-cell maturation antigen (BCMA), a protein highly expressed on malignant plasma cells in multiple myeloma. Unlike conventional CAR-T cells that utilize single-chain variable fragments (scFvs) as their antigen-binding domains, these constructs employ camelid-derived single-domain antibodies (also known as nanobodies or VHHs). Due to their smaller size, high stability, and lower propensity for tonic signaling, sdAb-based CARs can potentially offer enhanced tumor-killing efficacy, improved persistence, and reduced T-cell exhaustion. Preclinical development of these Canadian-made constructs, such as sdBCMA.41BB.CD3z and sdBCMA1.41BB.CD3z, is being led by the BC Cancer Research Institute, the National Research Council of Canada, and the Mayo Clinic, with evaluations ongoing in immunocompetent and xenograft models of multiple myeloma.
- Other names
- sdAb BCMA CAR-T cellssingle-domain antibody-based BCMA CAR-T cells
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on single-domain antibody BCMA CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on single-domain antibody BCMA CAR-T cells.